EDMONTON, Jan. 28 /CNW/ - Quest PharmaTech Inc. (“Quest” or the “Company”) today announced that it has signed a collaborative research agreement with the BC Cancer Agency (the “BCCA”) to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the Company’s lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.
